Treatment strategies for uterine leiomyoma: The role of hormonal modulation

Seminars in Reproductive Medicine

Volumn 22, Issue 2, 2004, Pages 105-111

  Cook, Jennifer D ^a   Walker, Cheryl Lyn ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antagonists; Hormone; Selective estrogen receptor modulators; Therapy; Uterine leiomyoma

Indexed keywords

AROMATASE; ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; CATECHOL ESTROGEN; CYTOCHROME P450; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FOLLITROPIN; FULVESTRANT; GONADORELIN AGONIST; GONADOTROPIN; HORMONE; LUTEINIZING HORMONE; LY 326315; MIFEPRISTONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID HORMONE; TAMOXIFEN; UNCLASSIFIED DRUG;

BONE ATROPHY; BONE DENSITY; BONE MINERAL; FEMALE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LIFESTYLE; MYOMECTOMY; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; TUMOR GROWTH; UTERUS MYOMA;

ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; LEIOMYOMA; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERINE NEOPLASMS;

EID: 2542418909     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828616     Document Type: Review

References (64)

1. Buttram V, Reiter R. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36:433-445
2. Cramer S, Patel B. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-438
3. Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986;293:359-362
4. Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988;72:853-857
5. Parazzini F, Negri E, La Vecchia C, et al. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992;79:430-433
6. Parazzini F, Negri E, La Vecchia C, et al. Uterine myomas and smoking. Results from an Italian study. J Reprod Med 1996;41:316-320
7. Parazzini F, Negri E, La Vecchia C, et al. Reproductive factors and risk of uterine fibroids. Epidemiology 1996;7:440-442
8. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996;41:483-490
9. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-973
10. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-439
11. Marshall LM, Spiegelman D, Manson JE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998;9:511-517
12. Chiaffarino F, Parazzini F, La Vecchia C, et al. Diet and uterine myomas. Obstet Gynecol 1999;94:395-398
13. Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999;106:857-860
14. Andreyko JL, Marshall LA, Dumesic DA, Jaffee RB. Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet Gynecol Surv 1987;42:1-21
15. Cohen D, Mazur MT, Jozefczyk MA, Badawy SZA. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy. J Reprod Med 1994;39:337-380
16. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992;166:746-751
17. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 1990;163(4 Pt 1):1114-1119
18. Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989;52:21-26
19. Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982;143:130-133
20. Yamamoto T, Takamori K, Okada H. Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res 1984;16:678-679
21. Rein M, Nowak R. Biology of uterine myomas and myometrium in vitro. Semin Reprod Endocrinol 1992;10:310-319
22. Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78-85
23. Brandon DD, Erickson TE, Keenan EJ, et al. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 1995;80:1876-1881
24. Englund K, Blanck A, Gustavsson I, et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 1998;83:4092-4096
25. Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-2850
26. Pollow K, Sinnecker G, Boquoi E, Pollow B. In vitro conversion of estradiol-17β into estrone in normal human myometrium and leiomyoma. J Clin Chem Clin Biochem 1978;16:493-502
27. Folkerd EJ, Newton CJ, Davidson K, Anderson MC, James VH. Aromatase activity in uterine leiomyomata. J Steroid Biochem 1984;20:1195-1200
28. Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994;78:736-743
29. Liehr JG, Ricci MJ, Jefcoate CR, et al. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci U S A 1995;92:9220-9224
30. Reddy VV, Hanjani P, Rajan R. Synthesis of catechol estrogens by human uterus and leiomyoma. Steroids 1981;37:195-203
31. Deligdish L, Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol 1970;23:676-680
32. Farrer-Brown G, Beilby JO, Tarbit MH. The vascular patterns in myomatous uteri. J Obstet Gynaecol Br Commonw 1970;77:967-975
33. Andersen JVM, DyReyes VM, Barbieri RL, Coachman DM, Miksicek RJ. Leiomyoma primary cultures have elevated transcriptional response to estrogen compared with autologous myometrial cultures. J Soc Gynecol Investig 1995;2:542-551
34. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;172(1 Pt 1):14-18
35. Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994;9:116-120
36. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-517
37. Kawaguchi K, Fuji S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989;160:637-641
38. Shimomura Y, Matsuo H, Samoto T, Maruo T. Upregulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998;83:2192-2198
39. Matsuo H, Maruo T, Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its upregulation by progesterone. J Clin Endocrinol Metab 1997;82:293-299
40. Hodges LC, Houston KD, Hunter DS, et al. Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells. Mol Cell Endocrinol 2002;196:11-20
41. Walker CL, Burroughs KD, Davis B, et al. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig 2000;7:249-256
42. Walker CL, Cesen-Cummings K, Houle C, et al. Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis 2001;22:2049-2052
43. Cesen-Cummings K, Houston KD, Copland JA, et al. Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling. J Soc Gynecol Investig 2003;10:11-20
44. Cesen-Cummings K, Copland JA, Barrett JC, Walker CL, Davis BJ. Pregnancy, parturition, and prostaglandins: defining uterine leiomyomas. Environ Health Perspect 2000;108(suppl 5):817-820
45. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-815
46. Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006-4010
47. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856
48. Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol 1995;76:1072-1073
49. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645
50. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647
51. Porter KB, Tsibris JC, Nicosia SV, et al. Estrogen-induced guinea pig model for uterine leiomyomas: do the ovaries protect? Biol Reprod 1995;52:824-832
52. Porter KB, Tsibris JC, Porter GW, et al. Effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol 1998;179:1283-1287
53. Yeung RS, Xiao GH, Jin F, et al. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci U S A 1994;91:11413-11416
54. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 1995;9:70-74
55. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker CL. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol 1995;146:1556-1567
56. Howe SR, Gottardis MM, Everitt JI, et al. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995;146:1568-1579
57. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 1996;17:151-159
58. Burroughs KD, Kiguchi K, Howe SR, et al. Regulation of apoptosis in uterine leiomyomata. Endocrinology 1997;138:3056-3064
59. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995;136:4996-5003
60. Palomba S, Sammartino A, Di Carlo C, et al. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 2001;76:38-43
61. Palomba S, Orio F, Morelli M, et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 2002;87:3603-3608
62. Palomba S, Russo T, Orio F, et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 2002;17:3213-3219
63. Palomba S, Orio F, Morelli M, et al. Raloxifene administration of women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab 2002;87:4476-4481
64. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003;14:247-250